|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/21 Evolutionary Genomics, Inc. 10-K 12/31/20 61:3.3M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 510K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 17K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 17K
12: R1 Document and Entity Information HTML 56K
13: R2 Consolidated Balance Sheets HTML 98K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
15: R4 Consolidated Statements of Operations HTML 76K
16: R5 Consolidated Statement of Stockholders' Equity HTML 59K
17: R6 Consolidated Statements of Cash Flows HTML 75K
18: R7 Business Activity HTML 22K
19: R8 Summary of Significant Accounting Policies HTML 29K
20: R9 New Accounting Standards HTML 27K
21: R10 Fair Value Measurements HTML 33K
22: R11 Property and Equipment HTML 28K
23: R12 Intangible Assets HTML 33K
24: R13 Income Taxes HTML 67K
25: R14 Notes Payable HTML 23K
26: R15 Stockholders' Equity and Warrants HTML 41K
27: R16 Stock-Based Compensation HTML 56K
28: R17 Commitments and Contingencies HTML 22K
29: R18 Related Parties and Transactions HTML 20K
30: R19 Concentrations HTML 19K
31: R20 Liquidity and Going Concern HTML 20K
32: R21 Summary of Significant Accounting Policies HTML 60K
(Policies)
33: R22 Fair Value Measurements (Tables) HTML 28K
34: R23 Property and Equipment (Tables) HTML 27K
35: R24 Intangible Assets (Tables) HTML 34K
36: R25 Income Taxes (Tables) HTML 67K
37: R26 Stockholders' Equity and Warrants (Tables) HTML 37K
38: R27 Stock-Based Compensation (Tables) HTML 55K
39: R28 Business Activity (Details) HTML 18K
40: R29 Summary of Significant Accounting Policies (Other) HTML 19K
(Details)
41: R30 Summary of Significant Accounting Policies HTML 22K
(Property and Equipment) (Details)
42: R31 Summary of Significant Accounting Policies HTML 24K
(Intangilbe Assets) (Details)
43: R32 Summary of Significant Accounting Policies (Net HTML 32K
Loss Per Common Share) (Details)
44: R33 Fair Value Measurements (Details) HTML 31K
45: R34 Property and Equipment (Details) HTML 34K
46: R35 Intangible Assets (Details) HTML 46K
47: R36 Income Taxes (Narrative) (Details) HTML 29K
48: R37 Income Taxes (Schedule of Income Tax Expense) HTML 40K
(Details)
49: R38 Income Taxes (Income Tax Reconciliation) (Details) HTML 46K
50: R39 Income Taxes (Schedule of Deferred Tax Assets and HTML 42K
Liabilities) (Details)
51: R40 Notes Payable (Details) HTML 49K
52: R41 Stockholders' Equity and Warrants (Narrative) HTML 45K
(Details)
53: R42 Stockholders' Equity and Warrants (Summary of HTML 40K
Warrants Activity) (Details)
54: R43 Stock-Based Compensation (Narrative) (Details) HTML 32K
55: R44 Stock-Based Compensation (Summary of Stock Options HTML 58K
Activity) (Details)
56: R45 Commitments and Contingencies (Details) HTML 26K
57: R46 Related Parties and Transactions (Details) HTML 21K
58: R47 Liquidity and Going Concern (Details) HTML 24K
60: XML IDEA XML File -- Filing Summary XML 106K
59: EXCEL IDEA Workbook of Financial Reports XLSX 57K
6: EX-101.INS XBRL Instance -- fnam-20201231 XML 841K
8: EX-101.CAL XBRL Calculations -- fnam-20201231_cal XML 161K
9: EX-101.DEF XBRL Definitions -- fnam-20201231_def XML 270K
10: EX-101.LAB XBRL Labels -- fnam-20201231_lab XML 703K
11: EX-101.PRE XBRL Presentations -- fnam-20201231_pre XML 503K
7: EX-101.SCH XBRL Schema -- fnam-20201231 XSD 105K
61: ZIP XBRL Zipped Folder -- 0001553350-21-000252-xbrl Zip 83K
| Certification |
EXHIBIT 31.2
CERTIFICATION
I, Steve Warnecke, certify that:
1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| |
|
|
BY: | /s/ Steve Warnecke |
| |
| Chief Financial Officer |
| (principal financial officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/31/21 | 10-Q | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/20 Evolutionary Genomics, Inc. 10-Q 9/30/20 57:30M Edgar Filing LLC/FA 3/30/20 Evolutionary Genomics, Inc. 10-K 12/31/19 61:4.4M Edgar Filing LLC/FA 4/01/19 Evolutionary Genomics, Inc. 10-K 12/31/18 61:29M Edgar Filing LLC/FA 3/05/18 Evolutionary Genomics, Inc. 10-K 12/31/17 59:3M Edgar Filing LLC/FA 2/10/17 Evolutionary Genomics, Inc. 10-K 12/31/16 66:3.8M Edgar Filing LLC/FA 2/25/16 Evolutionary Genomics, Inc. 8-K:3,5,9 2/22/16 3:136K Edgar Filing LLC/FA 2/19/16 Evolutionary Genomics, Inc. 10-K 12/31/15 63:6.2M Edgar Filing LLC/FA 10/23/15 Evolutionary Genomics, Inc. 8-K:2,3,4,510/19/15 7:265K Edgar Filing LLC/FA 7/02/15 Evolutionary Genomics, Inc. S-4/A 41:10M Edgar Filing LLC/FA 4/02/15 Evolutionary Genomics, Inc. S-4 36:3.3M Edgar Filing LLC/FA 3/05/15 Evolutionary Genomics, Inc. 10-K 12/31/14 35:2.1M Edgar Filing LLC/FA 9/23/10 Evolutionary Genomics, Inc. 10-12G 9/24/10 6:143K Precision Edgar/FA |